What question did this study set out to answer?

Determine whether cancer medicines listed on the WHO Model List of Essential Medicines align with frontline oncologists' priorities and evaluate their routine availability and financial burden across countries.

September 21, 2021The Lancet OncologyOpen Access

Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey

View Full Paper

Ask AI

Bookmark

Determine whether cancer medicines listed on the WHO Model List of Essential Medicines align with frontline oncologists' priorities and evaluate their routine availability and financial burden across countries.
Disseminated a 28-question electronic cross-sectional survey via hierarchical snowball sampling across 89 countries between Oct 15 and Dec 7, 2020.
Surveyed fully qualified adult medical oncologists (N=948 across 82 countries; 165 from low- and lower-middle-income, 165 from upper-middle-income, and 618 from high-income nations).
Queried the top ten cancer medications offering maximum public health benefit and evaluated universal availability alongside the risk of catastrophic expenditure (spending >40% of net non-food consumption).
The most frequently selected priority medicines were doxorubicin (53% [499/948]), cisplatin (50% [470/948]), paclitaxel (45% [423/948]), and pembrolizumab (44% [414/948]), with 19 of the top 20 (95%) currently listed on the WHO Essential Medicines List.
Universal availability for each top 20 medication ranged from 9% to 54% in low- and lower-middle-income countries, 13% to 90% in upper-middle-income countries, and 68% to 94% in high-income countries.
Risk of catastrophic health expenditure for the top 20 medicines was reported by 13% to 68% of oncologists in lower-middle-income settings, compared with 2% to 41% in upper-middle-income settings and 0% to 9% in high-income countries.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Cross-sectional survey reveals marked disparities in availability and affordability of essential cancer drugs globally, highlighting urgent barriers to routine clinical access.

Cite This Study

Fundytus et al. (2021) studied this question.

synapsesocial.com/papers/6a1a5aa7e916fa6dd3b879ee https://doi.org/10.1016/s1470-2045(21)00463-0

View Full Paper

Ask AI

Bookmark

Implication

Cross-sectional survey reveals marked disparities in availability and affordability of essential cancer drugs globally, highlighting urgent barriers to routine clinical access.

Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey

Key Points

Discussion

Implication

Cite This Study

Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider